SEP 1 3 7014 SUBSTITE (MODIFIE

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT (MODIFIED) PATENT AND TRAD			Attorney Docket No.		06132/075002 10/715,868			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))				Applicant Filing Date		Juan Arroyo November 17, 2003		
				Group IDS Filed		September 10, 2004		
			U.S. PATENTS			1		
Examiner's , initials	Patent Number or Publication Number	Issue Date or Publication Date			Class	Subclass	Filing Date (If Appropriate)	
FS	6,136,561	10/24/00	Ivy et al.		435	69,3		
	6,184,024 B1	02/06/01	Lai et al.		435	235.1		
	6,416,763 B1	07/09/02	McDonell et al.		424	218.1		
	6,696,281 B1	02/24/04	Chambers et al.		435	235.1		
PS	2003/0129201 A1	07/10/03	Monath et al.		424	718.		
	FOREIG	N PATENT OR PUE	BLISHED FOREIGN	PATENT A	PPLICATIO	IN .		
Examiner's Document Publication Initials Number Date			Country or Class Patent Office		Subclass	Translation (Yes/No)		
FS	WO 93/06214	04/01/93	WIPO					
	WO 98/37911	09/03/98	WIPO					
	WO 01/39802 A1	06/07/01	WIPO					
	WO 03/063725 A2	08/07/03	WIPO					
	OTHER DOCUM	ENTS (INCLUDING	AUTHOR, TITLE, D	ATE, PLAC	E OF PUBI	JCATION)		
	Arroyo et al., "Molecular Basis for Attenuation of Neurovirulence of a Yellow Fever Virus/Japanese Encephalitis Virus Chimera Vaccine (ChimeriVax-JE)," J. Virol. 75:934-942, 2001.							
	Arroyo et al., "Yellow Fever Vector Live-Virus Vaccines: West Nile Virus Vaccine Development," Trends in Molecular Medicine 7:350-354, 2001.							
	Bray et al., "Construction of Intertypic Chimeric Dengue Viruses by Substitution of Structural Protein Genes," Proc. Natl. Acad. U.S.A. 88:10342-10346, 1991.							
	1100:1100:71000:01		Caufour et al., "Construction, Characterization and Immunogenicity of Recombinant Yellow Fever 17D-Dengue Type 2 Virus Research 1-14, 2001.					
	Caufour et al., "Cons			genicity of R	ecombinan	t Yellow Feve	er 17D-Dengue	
	Caufour et al., "Cons	us Research 1-14, 2 utagenesis of the Ye	001. Illow Fever Virus NS	2B/3 Cleava	age Site: Do	eterminants o	of Cleavage Site	
Fs	Caufour et al., "Con: Type 2 Viruses," Viru Chambers et al., "M	us Research 1-14, 2 utagenesis of the Ye ts on Polyprotein Pre	001. Illow Fever Virus NS ocessing and Viral F	2B/3 Cleave Replication,"	age Site: Do	eterminants o :1600-1605,	of Cleavage Site 1995.	

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE			Attorney Docket No.	06132/075002		
			Serial No.	10/715,868		
			Applicant	Juan Arroyo		
	STATEMEN'	T BY APPLICANT		Filing Date	November 17, 2003	
	(Use several s	cheets if necessary)		Group	1642	
(37 C.F.R. § 1.98(b))		IDS Filed	September 10, 2004			
	OTHER DOCU	MENTS (INCLUDING AUTH	IOR, TITLE, C	ATE, PLACE OF PUBL	CATION)	
PS	Chambers et al., " J. Virol. 73:3095-3	Yellow Fever/Japanese Ence 101, 1999.	ephalitis Chim	eric Viruses: Construction	on and Biological Properties	
	Coia et al., "Nucleotide and Complete Amino Acid Sequences of Kunjin Virus: Definitive Gene Order Characteristics of the Virus-Specified Proteins," J. Gen. Virol. 69:1-21, 1988.					
	Davis et al., "West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge a Expresses In Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorb Assays," J. Virology 75:4040-4047, 2001. Duarte dos Santos et al., "Complete Nucleotide Sequence of Yellow Fever Virus Vaccine Strains 17DD and 213," Virus Research 35:35-41, 1995.					
Galler et al., "Genetic Variability Among Yellow Fever Virus 17D Substrains," Vaccine 16:1-5, Galler et al., "The Yellow Fever 17D Vaccine Virus: Molecular Basis of Viral Attenuation and it Expression Vector," Braz. J. Biol. Res. 30:157-168, 1997.					e 16:1-5, 1998.	
	Guirakhoo et al., "Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Youngue Virus Tetravalent Vaccine," J. Virol. 75:7290-7304, 2001. Guirakhoo et al., "Immunogenicity, Genetic Stability, and Protective Efficacy of a Recombinant, Chin Fever-Japanese Encephalitis Virus (ChimeriVax-JE) as a Live, Attenuated Vaccine Candidate Again Encephalitis," Virol. 257:363-372, 1999.					
	Lai et al., "Evaluation of Molecular Strategies to Develop a Live Dengue Vaccine," Clin. Diag. Virol. 10:1 1998. Mandl et al., "Sequence of the Genes Encoding the Structural Proteins of the Low-Virulence Tick-Borne Flaviviruses Langat TP21 and Yelantsev," Virol. 185:891-895, 1991.					
	Mandl et al., "Complete Genomic Sequence of Powassan Virus: Evaluation of Genetic Elements in Tick-Bo Versus Mosquito-Borne Flaviviruses," Virol. 194:173-184, 1993.					
	Marchevsky et al., "Phenotypic Analysis of Yellow Fever Virus Derived from Complementary DNA Tropical Medicine & Hygiene 52:75-80, 1995.					
	Monath et al., "Chimeric Yellow Fever Virus 17D-Japanese Encephalitis Virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing in Rhesus Monkeys," J. Virol. 74:1742-1751, 2000.					
125	Monath et al., "We	est Nile Virus Vaccine," Curre	ent Drug Targe	ets-Infectious Disorders	1:1-14, 2001.	
<u></u>						

	TITUTE FORM PTO-144			Attorney Docket No.	06132/075002			
(MODIFIED)		PATENT AND TRADEMARK OF	FFICE	Serial No.	10/715,868			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant	Juan Arroyo			
				Filing Date	November 17, 2003			
			1	Group	1642			
(37 C.F.R. § 1.98(b))				IDS Filed	September 10, 2004			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)								
FS		Pletnev et al., "Construction and Characterization of Chimeric Tick-Borne Encephalitis/Dengue Type 4 Viruses," Proc. Natl. Acad. Sci. U.S.A. 89:10532-10536, 1992.						
		Rice et al., "Transcription of Infectious Yellow Fever RNA from Full-Length cDNA Templates Produced by In Vitro Ligation," The New Biologist 1:285-296, 1989.						
		Shiu et al., "Genomic Sequence of the Structural Proteins of Louping III Virus: Comparative Analysis with Tick- Bome Encephalitis Virus," Virology 180:411-415, 1991.						
		Stocks et al., "Signal Peptidase Cleavage at the Flavivirus C-prM Junction: Dependence on the Viral NS2B-3 Protease for Efficient Processing Requires Determinants in C, the Signal Peptide, and prM," J. Virol. 72:2141-2149, 1998.						
		Van Der Most et al., "Chimeric Yellow Fever/Dengue Virus as a Candidate Dengue Vaccine: Quantitation of the Dengue Virus-Specific CD8 T-Cell Response," J. Virol. 74:8094-8101, 2000.						
F5	Venugopal et al., "Towards a New Generation of Flavivirus Vaccines," Vaccines 12:966-975, 1994.							
EXAMINER M Marco Pale DATE CONSIDERED 08/05/05								
EXAMINER: Initial citation considered. Braw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.								

(* a)